Novo Nordisk Dives As Next-Gen Obesity Drug Fails To Match Eli Lilly's Zepbound
Novo Nordisk Dives As Next-Gen Obesity Drug Fails To Match Eli Lilly's Zepbound is drawing significant interest across the industry.
Novo Nordisk stock dived after Novo's next-gen obesity drug CagriSema didn't match weight loss from Eli Lilly's Zepbound. Lilly stock rose.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Quantum computing India's ticket to leading role in global tech space: Chandrababu Naidu
- Pharmacy, biology, and education are among the worst-paying college majors-the 'AI proof' subjects pay Gen Z less than $50K after graduation
- Tech Startup Vama Launches Mega 'Vijay Anushthan' at Baglamukhi Temple, Ujjain for Semi
- Gainesville’s Iranian community watches war unfold at home
Source: Original →